Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-14 4:17 pm Purchase | 2026-03-31 | 13G | OVID THERAPEUTICS INC OVID | Affinity Asset Advisors, LLC | 15,635,484 9.100% | 3,486,318 (+28.70%) | Filing History |
| 2026-05-14 4:15 pm Purchase | 2026-03-31 | 13G | FORTE BIOSCIENCES INC FBRX | Affinity Asset Advisors, LLC | 1,011,890 7.300% | 176,926 (+21.19%) | Filing History |
| 2026-05-14 4:14 pm Sale | 2026-03-31 | 13G | VENTYX BIOSCIENCES INC VTYX | Affinity Asset Advisors, LLC | 0 0.000% | -6,465,041 (Position Closed) | Filing History |
| 2026-05-14 4:13 pm Purchase | 2026-03-31 | 13G | SUTRO BIOPHARMA INC STRO | Affinity Asset Advisors, LLC | 1,069,519 6.500% | 321,137 (+42.91%) | Filing History |
| 2026-05-14 4:11 pm Purchase | 2026-03-31 | 13G | IBIO INC PAR $0.001 IBIO | Affinity Asset Advisors, LLC | 3,489,048 9.990% | 1,087,432 (+45.28%) | Filing History |
| 2026-05-14 4:09 pm Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 1,340,840 5.500% | 289,786 (+27.57%) | Filing History |
| 2026-05-14 4:08 pm Purchase | 2026-03-31 | 13G | HELIX ACQUISITION CORP. III US HLXC | Affinity Asset Advisors, LLC | 1,250,000 7.000% | 1,250,000 (New Position) | Filing History |
| 2026-05-14 4:05 pm Purchase | 2026-03-31 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | Affinity Asset Advisors, LLC | 2,073,517 8.600% | 360,425 (+21.04%) | Filing History |
| 2026-01-29 9:33 pm Purchase | 2026-01-22 | 13G | NEXTCURE INC NXTC | Affinity Asset Advisors, LLC | 348,607 9.990% | 156,725 (+81.68%) | Filing History |
| 2026-01-29 9:32 pm Purchase | 2026-01-22 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | Affinity Asset Advisors, LLC | 1,713,092 8.600% | 1,048,868 (+157.91%) | Filing History |
| 2026-01-29 9:29 pm Purchase | 2026-01-22 | 13G | IBIO INC PAR $0.001 IBIO | Affinity Asset Advisors, LLC | 2,401,616 9.990% | 220,196 (+10.09%) | Filing History |
| 2026-01-29 7:59 pm Purchase | 2026-01-22 | 13G | VENTYX BIOSCIENCES INC VTYX | Affinity Asset Advisors, LLC | 6,465,041 9.000% | 2,407,936 (+59.35%) | Filing History |
| 2026-01-29 7:59 pm Unchanged | 2026-01-22 | 13G | VERRICA PHARMACEUTICALS INC CO VRCA | Affinity Asset Advisors, LLC | 884,172 5.500% | 0 (Unchanged) | Filing History |
| 2026-01-29 7:58 pm Purchase | 2026-01-22 | 13G | LEXEO THERAPEUTICS INC LXEO | Affinity Asset Advisors, LLC | 5,217,660 7.100% | 965,655 (+22.71%) | Filing History |
| 2026-01-29 7:58 pm Purchase | 2026-01-22 | 13G | SUTRO BIOPHARMA INC STRO | Affinity Asset Advisors, LLC | 748,382 8.800% | 90,005 (+13.67%) | Filing History |
| 2026-01-29 7:57 pm Sale | 2026-01-22 | 13G | FORTE BIOSCIENCES INC FBRX | Affinity Asset Advisors, LLC | 834,964 6.700% | -27,436 (-3.18%) | Filing History |
| 2026-01-29 7:57 pm Unchanged | 2026-01-22 | 13G | OVID THERAPEUTICS INC OVID | Affinity Asset Advisors, LLC | 12,149,166 9.000% | 0 (Unchanged) | Filing History |
| 2026-01-29 7:56 pm Purchase | 2026-01-22 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 1,051,054 5.700% | 44,837 (+4.46%) | Filing History |
| 2025-12-23 5:15 pm Purchase | 2025-12-17 | 13G | FORTE BIOSCIENCES INC FBRX | Affinity Asset Advisors, LLC | 862,400 6.900% | 862,400 (New Position) | Filing History |
| 2025-12-18 4:06 pm Purchase | 2025-12-11 | 13G | OVID THERAPEUTICS INC OVID | Affinity Asset Advisors, LLC | 12,149,166 9.000% | 12,149,166 (New Position) | Filing History |